Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A

Journal of Inflammation Research

Volumn 9, Issue , 2016, Pages 39-50

  Liu, Ling ^a   Lu, Jirong ^a   Allan, Barrett W ^b   Tang, Ying ^b   Tetreault, Jonathan ^a   Chow, Chi Kin ^a   Barmettler, Barbra ^b   Nelson, James ^b   Bina, Holly ^a   Huang, Lihua ^c   Wroblewski, Victor J ^b   Kikly, Kristine ^a  

^a Discovery Research   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c Bioproduct Research and Development   (United States)

Author keywords

Anti IL 17A; IL 17A monoclonal antibody; Ixekizumab

Indexed keywords

INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR; IXEKIZUMAB;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY COMBINING SITE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DISSOCIATION CONSTANT; DRUG BIOAVAILABILITY; DRUG PROTEIN BINDING; ELIMINATION HALF-LIFE; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PROTEIN PROTEIN INTERACTION; SEQUENCE ALIGNMENT;

EID: 84964879735     PISSN: None     EISSN: 11787031     Source Type: Journal    
DOI: 10.2147/JIR.S100940     Document Type: Article

References (3)

1. Huse WD, Sastry L, Iverson SA, et al. Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda. Science. 1989;246(4935):1275-1281.
2. Wu H, Beuerlein G, Nie Y, et al. Stepwise in vitro affinity maturation of Vitaxin, an alphav beta3-specific humanized mAb. Proc Natl Acad Sci U S A. 1998;95(11):6037-6042.
3. Wu H, Nie Y, Huse WD, Watkins JD. Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues. J Mol Biol. 1999;294(1):151-162.